Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?

Investors are relatively neutral on the industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 38.9x.

How does U.S. Clinical Research and Equipment compare with similar industries?

There is insufficient data on the sub-industries of this industry.

U.S. Clinical Research and Equipment Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Sun, 29 May 2022	US$773.5b	US$148.1b	US$20.1b	31.8x
Tue, 26 Apr 2022	US$804.5b	US$147.3b	US$25.4b	31.8x
Thu, 24 Mar 2022	US$846.7b	US$145.0b	US$25.3b	35.2x
Sat, 19 Feb 2022	US$825.6b	US$144.8b	US$25.4b	37.9x
Mon, 17 Jan 2022	US$878.1b	US$138.0b	US$27.3b	39.9x
Wed, 15 Dec 2021	US$960.7b	US$138.0b	US$27.3b	43.2x
Fri, 12 Nov 2021	US$963.1b	US$137.8b	US$27.1b	46.1x
Sun, 10 Oct 2021	US$709.1b	US$105.9b	US$18.6b	46x
Tue, 07 Sep 2021	US$754.5b	US$106.0b	US$18.6b	51.2x
Thu, 05 Aug 2021	US$718.4b	US$105.8b	US$18.7b	47.8x
Sun, 09 May 2021	US$604.0b	US$97.3b	US$17.5b	41.2x
Wed, 10 Feb 2021	US$596.2b	US$89.8b	US$14.6b	44.4x
Tue, 03 Nov 2020	US$465.9b	US$80.2b	US$11.9b	38.8x
Fri, 07 Aug 2020	US$440.2b	US$77.2b	US$8.9b	42.4x
Thu, 30 Apr 2020	US$355.0b	US$77.3b	US$8.5b	34.3x
Sun, 02 Feb 2020	US$349.5b	US$76.8b	US$8.6b	34x
Wed, 06 Nov 2019	US$324.1b	US$75.6b	US$7.0b	33.3x
Sat, 10 Aug 2019	US$334.7b	US$76.6b	US$8.3b	36.2x


US Market	6.18%
Healthcare	2.53%
Life Sciences	5.09%
Clinical Research and Equipment	5.09%

Company	Last Price	7D	1Y	Valuation
DHR Danaher	US$266.49	5.8% +US$10.5b	4.0%	PS30.7x
TMO Thermo Fisher Scientific	US$572.35	3.1% +US$6.7b	21.9%	PS29.5x
IQV IQVIA Holdings	US$220.50	9.3% +US$3.5b	-8.2%	PS38.7x
ILMN Illumina	US$258.06	6.0% +US$2.3b	-36.4%	PS57.8x
MTD Mettler-Toledo International	US$1.33k	7.1% +US$2.0b	2.0%	PS37.9x

May 24

Illumina, Inc. Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

Illumina, Inc. announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions including NTRK1, NTRK2 or NTRK3, and may benefit from targeted therapy with Bayer's VITRAKVI® (larotrectinib), in accordance with the approved therapeutic labeling. TSO Comprehensive (EU) is a comprehensive genomic profiling (CGP) test which combines less prevalent biomarkers with more prevalent ones in the same test, using a single biopsy specimen. This helps maximize the chances of identifying an actionable alteration so that patients can be treated with a targeted therapy or enrolled into a clinical trial based on their unique tumor genomic profile. The addition of this first CDx claim specific to NTRK gene fusions, a rare but highly actionable biomarker, helps provide patients harboring this genetic alteration with an opportunity to benefit from larotrectinib, a genomically matched treatment. Across most solid cancer tumor types, NTRK gene fusions can have a rare prevalence of 0.1-3% and can be challenging to detect as these genes fuse with many different partners, many of them previously unknown. Most CDx tests are specific to one type of cancer, but the NTRK claim is pan-cancer, enabling TSO Comprehensive (EU) to target multiple solid tumor types and a broad range of known and novel gene fusion partners across all three NTRK genes. This helps maximize the chances of finding actionable information from each patient's biopsy, to inform treatment with larotrectinib. The performance of TSO Comprehensive (EU) with NTRK fusions was assessed by analytical and clinical validation studies. Pooled data from three clinical trials, LOXO-TRK-14001 (NCT02122913), NAVIGATE (NCT02576431) and SCOUT (NCT02637687), were used to demonstrate the clinical effectiveness and safety of TSO Comprehensive (EU) in identifying NTRK1, NTRK2 and NTRK3 gene fusion positive patients who may be eligible for treatment with larotrectinib. The primary endpoint was the overall response rate (ORR), measured as the patient presenting either a complete response, a surgical complete response or partial response, to larotrectinib. Illumina has a growing pipeline of CDx claims under development through partnerships with pharmaceutical companies, which will be added to TSO Comprehensive (EU) following appropriate regulatory approvals. These CDx claims will help unlock targeted therapies and immunotherapies to make a difference in the lives of cancer patients. As Illumina continues to expand its broad portfolio of oncology partnerships with industry leaders, the company aims to advance cancer diagnostics and precision medicine.

U.S. Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

DHR

Is It Time To Consider Buying Danaher Corporation (NYSE:DHR)?

TMO

Executive VP & COO exercised options and sold US$7.4m worth of stock

A

Second quarter 2022 earnings: EPS misses analyst expectations

NOTV

Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization

TKNO

Chief Financial Officer recently bought US$94k worth of stock

MTD

Director recently sold US$5.9m worth of stock

ILMN

Illumina, Inc. Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

CDXC

Insider recently bought US$52k worth of stock

PKI

These 4 Measures Indicate That PerkinElmer (NYSE:PKI) Is Using Debt Reasonably Well

OMIC

Lead Independent Director recently bought US$89k worth of stock

WST

Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?

APDN

Consensus revenue estimates increase by 20%

NAUT

Co-Founder recently bought US$198k worth of stock

STVN

Stevanato Group S.P.A. Recommends Cash Dividend

DNAY

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

IQV

IQVIA A Smart Choice In A High-Inflation Environment